Sarah Mason

3.1k total citations
48 papers, 2.0k citations indexed

About

Sarah Mason is a scholar working on Cellular and Molecular Neuroscience, Neurology and Molecular Biology. According to data from OpenAlex, Sarah Mason has authored 48 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Cellular and Molecular Neuroscience, 31 papers in Neurology and 27 papers in Molecular Biology. Recurrent topics in Sarah Mason's work include Genetic Neurodegenerative Diseases (39 papers), Neurological disorders and treatments (29 papers) and Mitochondrial Function and Pathology (20 papers). Sarah Mason is often cited by papers focused on Genetic Neurodegenerative Diseases (39 papers), Neurological disorders and treatments (29 papers) and Mitochondrial Function and Pathology (20 papers). Sarah Mason collaborates with scholars based in United Kingdom, United States and Canada. Sarah Mason's co-authors include Roger A. Barker, Gavin P. Reynolds, Nicola Pavese, Yen Tai, Paola Piccini, David J. Brooks, Anna Goodman, Wei‐Li Kuan, Sarah J. Tabrizi and Erik H.F. Wong and has published in prestigious journals such as Annals of Neurology, Journal of Neurochemistry and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Sarah Mason

48 papers receiving 1.9k citations

Peers

Countries citing papers authored by Sarah Mason

Since Specialization

Citations

This map shows the geographic impact of Sarah Mason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Mason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Mason more than expected).

Fields of papers citing papers by Sarah Mason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Mason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Mason. The network helps show where Sarah Mason may publish in the future.

Co-authorship network of co-authors of Sarah Mason

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Mason. A scholar is included among the top collaborators of Sarah Mason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Mason. Sarah Mason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploring the predictors of financial impairment in Huntington’s disease using the Enroll-HD dataset 2022 ·Journal of Neurology ·Kate Harris, Sarah Mason, Roger A. Barker	3
2	The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of Huntington’s Disease Patients 2020 ·Journal of Huntington s Disease ·(unknown), Sarah Mason, Roger A. Barker	12
3	A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice 2019 ·Frontiers in Neurology ·Christopher J. Heath, Claire O’Callaghan, Sarah Mason, Benjamin U. Phillips, Lisa M. Saksida, Trevor W. Robbins, Roger A. Barker, Timothy J. Bussey, Barbara J. Sahakian	22
4	Huntington's disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory 2019 ·Cortex ·Kate Harris, (unknown), Rachel Swain, Sharon Erzinçlioğlu, Tilak Das, Neil Burgess, Roger A. Barker, Sarah Mason	35
5	Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease 2018 ·PubMed ·Stéphane Palfi, (unknown), H. Lepetit, (unknown), G. Ralph, Sarah Mason, (unknown), Philippe Domenech, Philip C. Buttery, Philippe Hantraye, (unknown), Roger A. Barker, Kyriacos Mitrophanous	105
6	Platelet abnormalities in Huntington’s disease 2018 ·Journal of Neurology Neurosurgery & Psychiatry ·Hélèna L. Denis, Jérôme Lamontagne‐Proulx, Isabelle St‐Amour, Sarah Mason, Jesse W. Rowley, Nathalie Cloutier, Marie‐Ève Tremblay, Antony T. Vincent, Peter V. Gould, Sylvain Chouinard, Andrew S. Weyrich, Matthew T. Rondina, Roger A. Barker, Éric Boilard, Francesca Cicchetti	35
7	An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease 2017 ·Journal of Neurology ·Benjamin R. Underwood, (unknown), Peter J. Pugh, Stanley E. Lazic, Sarah Mason, Julian L. Griffin, P. Simon Jones, James B. Rowe, David C. Rubinsztein, Roger A. Barker	23
8	Hippocampal dysfunction defines disease onset in Huntington's disease 2016 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Laetitia Schwab, Sarah Mason, Roger A. Barker	49
9	Novel targets for Huntington’s disease: future prospects 2016 ·PubMed ·Sarah Mason, Roger A. Barker	9
10	Dopamine and Huntington’s disease 2015 ·Expert Review of Neurotherapeutics ·Laetitia Schwab, (unknown), Janelle Drouin‐Ouellet, Sarah Mason, Simon Stott, Roger A. Barker	54
11	The role of the amygdala during emotional processing in Huntington's disease: From pre-manifest to late stage disease 2015 ·Neuropsychologia ·Sarah Mason, Jiaxiang Zhang, (unknown), Natalie Valle Guzman, Alpár S. Lázár, James B. Rowe, Roger A. Barker, Adam Hampshire	38
12	Progress in Huntington’s disease: the search for markers of disease onset and progression 2015 ·Journal of Neurology ·Sarah Mason, Roger A. Barker	5
13	The Addenbrooke’s Cognitive Examination-Revised accurately detects cognitive decline in Huntington’s disease 2013 ·Journal of Neurology ·(unknown), (unknown), Gemma Cummins, Lucy Collins, Natalie Valle Guzman, Sarah Mason, Roger A. Barker	15
14	Huntington’s disease: changes in saccades and hand-tapping over 3 years 2010 ·Journal of Neurology ·Chrystalina A. Antoniades, Zheyu Xu, Sarah Mason, R. H. S. Carpenter, Roger A. Barker	39
15	The relation between anger and different forms of disgust: Implications for emotion recognition impairments in Huntington's disease 2010 ·Neuropsychologia ·Andrew J. Calder, Jill Keane, Andrew W. Young, Andrew D. Lawrence, Sarah Mason, Roger A. Barker	61
16	Emerging drug therapies in Huntington's disease 2009 ·Expert Opinion on Emerging Drugs ·Sarah Mason, Roger A. Barker	25
17	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers 2009 ·Neurobiology of Disease ·Nicola Pavese, Marios Politis, Yen Tai, Roger A. Barker, Sarah J. Tabrizi, Sarah Mason, David J. Brooks, Paola Piccini	39
18	Health‐related quality of life in Huntington's disease: Which factors matter most? 2008 ·Movement Disorders ·Aileen K. Ho, (unknown), Sarah Mason, Anna Goodman, Roger A. Barker	119
19	Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease 2008 ·Journal of Neurology Neurosurgery & Psychiatry ·Iris Reuter, Yen Tai, Nicola Pavese, К. Ray Chaudhuri, Sarah Mason, Charles E. Polkey, (unknown), David J. Brooks, Roger A. Barker, Paola Piccini	87
20	Are Striatal Dopamine D₄ Receptors Increased in Schizophrenia? 1994 ·Journal of Neurochemistry ·Gavin P. Reynolds, Sarah Mason	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact